I don't know this company very well but quickly looked at their website after reading that the company authored this article. They recently issued a press relea

I don't know this company very well but quickly looked at their website after reading that the company authored this article. They recently issued a press release with the headline that 4 of 5 patients treated with their drug had a partial response. Reading further in the press release shows that 10 total patients were treated, 8 have been assessed, and one of those partial responses was unconfirmed. I haven't looked at the data and don't know the indication well enough to know it 3 or 4 partial responses from 10 patients is good. However i find the company's positioning of the data a bit misleading. For what it's worth, the stock is down a good amount since they announced this data The wording of that study update combined with the excited yet data-light SA article is a bit concerning. I hope this does not make patients think this potential therapy is more promising than it actually is http://ir.adaptimmune.com/phoenix.zhtml?c=253991&p=irol-newsArticle&ID=2397170 http://ir.adaptimmune.com/phoenix.zhtml?c=253991&p=irol-news...